The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Unmet needs in developing immune therapies for amyloidosis & ongoing research in the field
Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, comments on the potential of immunotherapies in treating light chain (AL) amyloidosis, stating that while there have been promising results with CAR T-cell therapy and bispecific antibodies in multiple myeloma, the field is still in its early stages for AL amyloidosis. He highlights ongoing efforts to investigate the efficacy and safety of these immunotherapies in amyloidosis. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
